Lupus News

WASHINGTON — A hazard index tool based on short-term renal parameters predicted long-term outcomes in patients with lupus nephritis, according to data presented at the American College of Rheumatology Annual Meeting.

WASHINGTON — The renal activity in lupus urinary biomarker algorithm can predict treatment response, according to data presented at the American College of Rheumatology Annual Meeting.

Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody under development by MedImmune, was effective against moderate to severe systemic lupus erythematosus, according to phase 2b trial results.

Compared to patients with osteoarthritis, patients with lupus did not have an increased risk for adverse events in the first 6 months after a total knee arthroplasty, according to a study of 166 patients.

An interleukin-6 monoclonal antibody — as a 10 mg dose — improved the composite response of patients with lupus, according to recent phase 2 trial.

Patients with moderately to severely active systemic lupus erythematosus who were treated with epratuzumab plus standard therapy did not show improvements in response rates compared with patients who received placebo plus standard therapy, according to results.

Monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus allowed physicians to identify noncompliance and made dose titration easier.

The development of anti-tumor necrosis factor-alpha–based therapies for the treatment of Crohn’s disease and ulcerative colitis has been a major advance in the management of these conditions.

Patients with systemic lupus erythematosus had different subtypes of microparticle-containing immune complexes that were associated with distinct clinical characteristics, including disease activity and vascular damage, recently published results showed.

The Pharmaceutical Research and Manufacturers of America and the Lupus Foundation of America released a report that showed biopharmaceutical research companies in the United States have 311 medicines and vaccines in clinical trials or pending review by the FDA for patients with autoimmune disease.